News

News Dec 13, 2024

This Week in Drug Pricing: Pharma’s Excessive Prices Hikes, Inhaler Pricing Schemes, Big Pharma’s Patent Abuses Cost Patients & Taxpayers and ICYMI

The new report from the Institute for Clinical and Economic Review (ICER) on price increases of prescription drugs in the U.S. established that five of the top 10 drugs with price hikes above the…

Read Article News Dec 9, 2024

This Week in Drug Pricing: First Patient Advocate of the Year, Healthcare Package Negotiations Heat Up, and ICYMI

P4AD proudly began a new tradition: our Patient Advocate of the Year Award. The award honors a patient advocate who has gone above and beyond in the fight for lower drug prices.

Read Article News Nov 22, 2024

This Week in Drug Pricing: PREVAIL Act Narrowly Clears Senate Judiciary Committee, Continued Push For Competition, President-Elect Trump 2025 Appointments, and ICYMI

After several delays, members of the Senate Judiciary Committee voted to pass S. 2220, the PREVAIL Act, by a razor-thin bipartisan margin of 11 yays to 10 nays.

Read Article News Nov 21, 2024

Patients For Affordable Drugs Now Expresses Disappointment Over Senate Judiciary Committee’s Advancement Of Patent Bill That Will Keep Drug Prices High For Patients

Patients For Affordable Drugs Now is disappointed to see the Senate Judiciary Committee advance a patent bill that would harm patients: S. 2220 the PREVAIL Act.

Read Article News Nov 15, 2024

This Week in Drug Pricing: Harmful Patent Bills Stall In Senate, Drug Industry Trade Association’s Waning Power and ICYMI

The Senate Judiciary Committee’s markup of two controversial patent bills, S.2220, the PREVAIL Act, and S.2140, the Patent Eligibility Restoration Act (PERA), was postponed yet again amidst ongoing…

Read Article News Nov 8, 2024

This Week in Drug Pricing: P4ADNow’s Commitment To Lower Prices Under New Administration, CAR-T: A Breakthrough Therapy Hindered By High Costs, and ICYMI

With the 2024 Presidential Election called for Former President Donald Trump, P4ADNow reiterated its commitment to addressing the high cost of prescription drugs through working with the incoming…

Read Article News Nov 1, 2024

This Week in Drug Pricing: Court Watch: US v. Pharma, Big Pharma Reaps Big Earnings, and ICYMI

Combined oral arguments brought by Bristol Myers Squibb (BMS), AstraZeneca, and Janssen Pharmaceuticals were heard by the Third Court of Appeals in Philadelphia in their efforts to halt the Medicare Negotiation Program.

Read Article News Oct 25, 2024

This Week in Drug Pricing: Court Watch: US v. Pharma, First Patient Leaves Hospital After SCD Therapy, Legislators Tout IRA Savings, and ICYMI

Marking another significant upset for Big Pharma and a critical victory for patients, Novartis faced a setback last week in its lawsuit to stop the implementation of the Medicare Negotiation Program.

Read Article News Oct 18, 2024

This Week in Drug Pricing: Court Watch: US v. Pharma, Bringing CAR-T Closer To Patients, Medicare “Smoothing” OOP Costs, and ICYMI

Novo Nordisk’s legal battle against the Medicare Negotiation Program has shifted gears, with the company now focusing on challenging elements of the program’s implementation rather than broad…

Read Article News Oct 11, 2024

This Week in Drug Pricing: Projected Savings From Out-of-Pocket Cap, Rising Prices Of Cancer Therapies, Patient Advocates At HHS Roundtable, and ICYMI

Asthma and chronic obstructive pulmonary disease (COPD) disproportionately affects Black, Latino, and Native American communities, as a result of key social determinants of health – such as air…

Read Article